Timeline of key events in biotechnology

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

Twenty-two patients were treated in the trial over 42 months in six centres around the world. The treatment consisted of taking immature stem cells from the patient's bone marrow and using a harmless virus to infect the cells with a copy of the normal globin gene. The new genetically altered cells were then reintroduced into the patient's bloodstream after their marrow had been cleared of diseased cells using chemotherapy. Nine out of the twenty-two patients severe beta thalassemia were able to cut down on the number of transfusions they needed by 74%, with three of them no longer needing any transfusions at all. The same was true of the twelve out of thirteen patients with less severe thalassemia. A A Thompson et al, 'Gene therapy in patients with transfusion-dependent beta thalassemia', New England Journal of Medicine, 378 (2018), 1479-93.2018-04-19T00:00:00+0000
Date Event People Places Sciences
19 Apr 2018Gene therapy shown to be promising treatment in clinical trials for beta thalassemiaThompson, Walters, Kwiatkowski, Rasko, Ribeil, Hongeng, Magrin, Schiller, Payen, Smeraro, Moshous, LefrerNorth Western University, University of California San Francisco, University of California Los Angeles, University of Sydney, University of Paris, Harvard University, Mahidol University, German Cancer Research CentreGene therapy

19 Apr 2018

Gene therapy shown to be promising treatment in clinical trials for beta thalassemia